K
Kortuc
A novel radiosensitizer for cancer radiotherapy
About Kortuc
KORTUC is a pioneering startup that operates in the healthcare sector, specifically focusing on cancer treatment. The company has developed an innovative solution to address hypoxia, a fundamental issue in cancer that involves a lack of oxygen reaching the tissues. This is a significant breakthrough as hypoxia often makes tumors resistant to radiotherapy, a common cancer treatment.
KORTUC's solution is a radiosensitizer, primarily composed of H2O2 (hydrogen peroxide), which is injected directly into the tumor. This radiosensitizer eliminates hypoxia, making the tumor more sensitive to radiotherapy. In simple terms, it boosts the effectiveness of radiotherapy, providing a more potent option for cancer treatment.
The company's research and development efforts have been recognized in reputable publications such as "Cancer Science" and "Oncology Letters". This suggests that KORTUC is at the forefront of cancer research, contributing to the advancement of treatment options.
KORTUC's business model revolves around the development and commercialization of its innovative radiosensitizer. The company's primary clients are healthcare providers who administer radiotherapy to cancer patients. By offering a solution that enhances the effectiveness of existing treatments, KORTUC is positioned to generate revenue through the sale of its product.
Looking ahead, KORTUC plans to continue its research and development activities to further refine its product and potentially develop new solutions. The company's team, composed of its founding members and other professionals, is dedicated to fulfilling its mission of providing more options for cancer radiotherapy.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Palo Alto, United States
- Employees
- 3
- Open positions
- None listed
- Dealroom signal
- 58.2/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Radiotherapy, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Dec 2024 | $0 | — | Alfresa · Shikoku Alfresa | ↗ |
| LATE VCOther financing | May 2023 | $109M | $435M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Kortuc is 4.5K monthly website visits, up 309.1% over the last three months. Kortuc's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Nissay Capital
Series B and later7 investors entered at this stage
Iyogin Capital
Pegasus Tech Ventures
SBI Investment- IGIrimajiri Group
AXA Life Japan
Alfresa- SAShikoku Alfresa
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Kortuc on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Kortuc’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







